|
1
|
Ozdemirli M, Loughney TM, Deniz E, Chahine JJ, Albitar M, Pittaluga S, Sadigh S, Armand P, Uren A, Anderson KC. Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy. N Engl J Med 2024; 390:2074-2082. [PMID: 38865661 DOI: 10.1056/nejmoa2401530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/14/2024]
Abstract
Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for treatment of myeloma. Targeted messenger RNA sequencing revealed the presence of CAR gene product in tumor cells. Whole-genome sequencing of samples of tumor and peripheral blood identified a single lentiviral insertion site within the second intron of the SSU72 gene. In addition, numerous genetic alterations that may have contributed to malignant transformation were identified in the tumor sample. (Funded by MedStar Georgetown University Hospital.).
Collapse
MESH Headings
- Humans
- Male
- Middle Aged
- Biological Products/administration & dosage
- Biological Products/therapeutic use
- CD4-Positive T-Lymphocytes/immunology
- Immunotherapy, Adoptive/adverse effects
- Immunotherapy, Adoptive/methods
- Lymphoma, T-Cell/etiology
- Lymphoma, T-Cell/genetics
- Lymphoma, T-Cell/immunology
- Lymphoma, T-Cell/therapy
- Multiple Myeloma/genetics
- Multiple Myeloma/immunology
- Multiple Myeloma/therapy
- Receptors, Antigen, T-Cell/genetics
- Receptors, Antigen, T-Cell/therapeutic use
- Receptors, Chimeric Antigen/therapeutic use
- Receptors, Chimeric Antigen/immunology
- Antineoplastic Agents, Immunological/adverse effects
- Antineoplastic Agents, Immunological/therapeutic use
Collapse
Affiliation(s)
- Metin Ozdemirli
- From the Departments of Pathology (M.O., J.J.C.) and Gastroenterology (T.M.L.), MedStar Georgetown University Hospital, and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center (E.D., A.U.) - both in Washington, DC; the Genomic Testing Cooperative, Irvine, CA (M.A.); the National Institutes of Health, Bethesda, MD (S.P.); and Brigham and Women's Hospital (S.S.), the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (K.C.A.), and Harvard Medical School (P.A.) - all in Boston
| | - Thomas M Loughney
- From the Departments of Pathology (M.O., J.J.C.) and Gastroenterology (T.M.L.), MedStar Georgetown University Hospital, and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center (E.D., A.U.) - both in Washington, DC; the Genomic Testing Cooperative, Irvine, CA (M.A.); the National Institutes of Health, Bethesda, MD (S.P.); and Brigham and Women's Hospital (S.S.), the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (K.C.A.), and Harvard Medical School (P.A.) - all in Boston
| | - Emre Deniz
- From the Departments of Pathology (M.O., J.J.C.) and Gastroenterology (T.M.L.), MedStar Georgetown University Hospital, and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center (E.D., A.U.) - both in Washington, DC; the Genomic Testing Cooperative, Irvine, CA (M.A.); the National Institutes of Health, Bethesda, MD (S.P.); and Brigham and Women's Hospital (S.S.), the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (K.C.A.), and Harvard Medical School (P.A.) - all in Boston
| | - Joeffrey J Chahine
- From the Departments of Pathology (M.O., J.J.C.) and Gastroenterology (T.M.L.), MedStar Georgetown University Hospital, and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center (E.D., A.U.) - both in Washington, DC; the Genomic Testing Cooperative, Irvine, CA (M.A.); the National Institutes of Health, Bethesda, MD (S.P.); and Brigham and Women's Hospital (S.S.), the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (K.C.A.), and Harvard Medical School (P.A.) - all in Boston
| | - Maher Albitar
- From the Departments of Pathology (M.O., J.J.C.) and Gastroenterology (T.M.L.), MedStar Georgetown University Hospital, and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center (E.D., A.U.) - both in Washington, DC; the Genomic Testing Cooperative, Irvine, CA (M.A.); the National Institutes of Health, Bethesda, MD (S.P.); and Brigham and Women's Hospital (S.S.), the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (K.C.A.), and Harvard Medical School (P.A.) - all in Boston
| | - Stefania Pittaluga
- From the Departments of Pathology (M.O., J.J.C.) and Gastroenterology (T.M.L.), MedStar Georgetown University Hospital, and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center (E.D., A.U.) - both in Washington, DC; the Genomic Testing Cooperative, Irvine, CA (M.A.); the National Institutes of Health, Bethesda, MD (S.P.); and Brigham and Women's Hospital (S.S.), the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (K.C.A.), and Harvard Medical School (P.A.) - all in Boston
| | - Sam Sadigh
- From the Departments of Pathology (M.O., J.J.C.) and Gastroenterology (T.M.L.), MedStar Georgetown University Hospital, and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center (E.D., A.U.) - both in Washington, DC; the Genomic Testing Cooperative, Irvine, CA (M.A.); the National Institutes of Health, Bethesda, MD (S.P.); and Brigham and Women's Hospital (S.S.), the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (K.C.A.), and Harvard Medical School (P.A.) - all in Boston
| | - Philippe Armand
- From the Departments of Pathology (M.O., J.J.C.) and Gastroenterology (T.M.L.), MedStar Georgetown University Hospital, and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center (E.D., A.U.) - both in Washington, DC; the Genomic Testing Cooperative, Irvine, CA (M.A.); the National Institutes of Health, Bethesda, MD (S.P.); and Brigham and Women's Hospital (S.S.), the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (K.C.A.), and Harvard Medical School (P.A.) - all in Boston
| | - Aykut Uren
- From the Departments of Pathology (M.O., J.J.C.) and Gastroenterology (T.M.L.), MedStar Georgetown University Hospital, and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center (E.D., A.U.) - both in Washington, DC; the Genomic Testing Cooperative, Irvine, CA (M.A.); the National Institutes of Health, Bethesda, MD (S.P.); and Brigham and Women's Hospital (S.S.), the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (K.C.A.), and Harvard Medical School (P.A.) - all in Boston
| | - Kenneth C Anderson
- From the Departments of Pathology (M.O., J.J.C.) and Gastroenterology (T.M.L.), MedStar Georgetown University Hospital, and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center (E.D., A.U.) - both in Washington, DC; the Genomic Testing Cooperative, Irvine, CA (M.A.); the National Institutes of Health, Bethesda, MD (S.P.); and Brigham and Women's Hospital (S.S.), the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (K.C.A.), and Harvard Medical School (P.A.) - all in Boston
| |
Collapse
|
|
2
|
Fidler E, Dwyer K, Ansari A. Ssu72: a versatile protein with functions in transcription and beyond. Front Mol Biosci 2024; 11:1332878. [PMID: 38304578 PMCID: PMC10830811 DOI: 10.3389/fmolb.2024.1332878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Accepted: 01/08/2024] [Indexed: 02/03/2024] Open
Abstract
Eukaryotic transcription is a complex process involving a vast network of protein and RNA factors that influence gene expression. The main player in transcription is the RNA polymerase that synthesizes the RNA from the DNA template. RNA polymerase II (RNAPII) transcribes all protein coding genes and some noncoding RNAs in eukaryotic cells. The polymerase is aided by interacting partners that shuttle it along the gene for initiation, elongation and termination of transcription. One of the many factors that assist RNAPII in transcription of genes is Ssu72. It is a carboxy-terminal-domain (CTD)-phosphatase that plays pleiotropic roles in the transcription cycle. It is essential for cell viability in Saccharomyces cerevisiae, the organism in which it was discovered. The homologues of Ssu72 have been identified in humans, mice, plants, flies, and fungi thereby suggesting the evolutionarily conserved nature of the protein. Recent studies have implicated the factor beyond the confines of transcription in homeostasis and diseases.
Collapse
Affiliation(s)
| | | | - Athar Ansari
- Department of Biological Sciences, Wayne State University, Detroit, MI, United States
| |
Collapse
|